Table 1 Baseline characteristics.

From: Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer

Characteristics

Total (N = 111)

Age—year

Median

65

Range

31–87

Age ≥ 65

57 (51.4%)

ECOG

0–1

79 (71.2%)

2

32 (28.8%)

Sex, n (%)

Male

80 (72.1%)

Female

31 (27.9%)

Metastases

1

44 (39.6%)

 ≥ 2

67 (60.4%)

Surgery

No

72 (64.9%)

Subtotal gastrectomy

22 (19.8%)

Total gastrectomy

17 (15.3%)

Height (m), mean ± SD

162.6 ± 9.0

Weight (kg), mean ± SD

58.2 ± 12.3

BMI, kg/m2

Underweight < 20

34 (30.6%)

Normal 20–24.9

60 (54.1%)

Overweight > 25

17 (15.3%)

L3 Skeletal muscle index (cm2/m2)

40.7 ± 9.0

Sarcopenia, n (%)

52 (46.8%)

Hemoglobin (g/dL), median (range)

10.9 (4.0–15.4)

Serum albumin (g/dL)

Median (range)

3.6 (1.5–4.7)

 < 3.5 g/dL

45 (40.5%)

First-line regimen

S-1/cisplatin or XP

13 (11.7%)

FOLFOX or XELOX

78 (70.3%)

Trastuzumab plus XP

11 (9.9%)

S-1 or capecitabine

9 (8.1%)

  1. Sarcopenia was defined as an L3 skeletal muscle index of < 49 cm2/m2 for men and < 31 cm2/m2 for women using Korean-specific cutoffs.
  2. SMI skeletal muscle index, ECOG Eastern Cooperative Oncology Group, BMI body mass index, FOLFOX 5-fluorouracil, leucovorin, and oxaliplatin, XELOX capecitabine and oxaliplatin, XP capecitabine and cisplatin, ORR overall response rate.
Back to article page